期刊文献+

非心瓣膜病心房颤动患者血清亲环素A和基质金属蛋白酶的表达水平及临床意义

下载PDF
导出
摘要 目的检测非心瓣膜病心房颤动患者血清中亲环素A(CyPA)和基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)的表达,探讨它们在心房颤动中的临床意义。方法观察组为非心瓣膜病心房颤动患者140例(房颤组,其中阵发性房颤45例、持续性房颤48例、永久性房颤47例),选取我科同期住院条件相同的窦性心律非心瓣膜病患者135例为对照组(非房颤组)。采用ELISA法检测各组患者血清中CyPA、MMP-2、MMP-9水平,同时测量左心房前后径(LAD),探讨CyPA和MMP-2、MMP-9在不同临床特征患者中表达的意义及相关性。结果观察组血清中CyPA和MMP-2、MMP-9表达水平显著高于对照组(P<0.01),观察组中CyPA和MMP-2、MMP-9的表达与心房颤动持续时间密切相关。观察组左心房前后径大于对照组(P<0.01),且与房颤动持续时间密切相关。经线性相关分析显示观察组患者血清中CyPA与MMP-2、MMP-9水平呈正相关(阵发性房颤组r1=0.77、r2=0.80,P<0.01;持续性房颤组r1=0.71、r2=0.76,P<0.01;永久性房颤组r1=0.67、r2=0.74,P<0.05);CyPA浓度与LAD呈正相关(阵发性房颤组r=0.72,P<0.01;持续性房颤组r=0.74,P<0.01;永久性房颤组r=0.65,P<0.05);MMP-2、MMP-9水平与LAD呈正相关(阵发性房颤组r1=0.74、r2=0.76,P<0.01;持续性房颤组r1=0.66、r2=0.68,P<0.01;永久性房颤组r1=0.63、r2=0.72,P<0.05)。结论 CyPA和基质金属蛋白酶(MMP-2、MMP-9)在心房颤动患者血清中高表达,二者的协同作用在房颤的维持和发展中具有重要促进作用,CyPA和MMP-2、MMP-9的联合检测对评估心房颤动患者的病变程度及临床治疗具有一定的指导作用。
出处 《心血管病防治知识(学术版)》 2014年第7期76-78,共3页 Prevention and Treatment of Cardiovascular Disease
基金 安徽省自然科学基金 编号:10040606Q44 教育部第46批"留学回国人员科研启动基金"
  • 相关文献

参考文献4

二级参考文献31

  • 1Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardilvasc Res, 2000, 46:225-238.
  • 2Saharinen J, Hyytiainen M, Taipale J, et al. Latent transforming growth factor-beta binding proteins ( LTBPs ) structural extracellular nmtrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev, 1999, 10 : 99-117.
  • 3Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression int infracted rat. Cardiovasc Res, 2000, 46:307-315.
  • 4Nagahiro N, Kazuhiro Y, Yasushi S, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res, 2003, 57:766-774.
  • 5Ducharme A , Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 2000, 106:55-62.
  • 6Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metallproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure . Nat Med, 1999, 5:1135-1142.
  • 7Borg TK, Burgess ML. Holding it all together: organization and function(s) of the extracellular matrix of the heart. Heart Failure,1993,8 : 230-238.
  • 8Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.Circulation, 1998, 98 : 1728-1734.
  • 9Roten L, Nemoto S, Simsic J, et al. Effects of gene diletion of the tissue inhibitor of the matrix metalloproteinase-type 1 ( TIMP-1 ) on left ventricular geometry and function in mice. J Mol Cell Cardiol,2000, 32:109-120.
  • 10Nattel S. New ideas about atrial fibrillation 50 years on. Nature,2002 ,415:219-226.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部